ACM Biolabs
ACM Biolabs is a biotechnology company founded in Singapore in 2013, with subsidiaries in Switzerland and Australia. It specializes in developing next-generation medicines, vaccines, and personalized immunotherapies using its proprietary thermostable polymer-based nanoparticle delivery platform, ATP™. The company aims to revolutionize targeted drug delivery, improve vaccine stability and efficacy, and address unmet medical needs across various therapeutic areas including infectious diseases, oncology, and ophthalmology. It is actively involved in developing prophylactic and therapeutic vaccines, including a second-generation COVID-19 vaccine candidate, ACM-001, which is based on its innovative ACM platform technology (Artificial Cell Membranes). The company collaborates with academic and industry partners, such as Dr. Steve Pascolo from the University Hospital Zurich, supported by Innosuisse, the Swiss Innovation Agency, to develop stable mRNA vaccines with improved storage and distribution properties. ACM Biolabs also advances intranasal vaccine formulations that induce systemic and mucosal immunity, capable of neutralizing multiple SARS-CoV-2 variants including Omicron, Delta, and Beta. The company has received recognition for its innovative platform and research, including a prestigious Innosuisse grant, and actively participates in industry events like the NTUitive’s Technology Roadshow and the J.P. Morgan Healthcare Conference. Its research includes the development of multicompartmentalized polymersomes for selective encapsulation of biomacromolecules, mimicking cellular compartmentalization, and exploring intranasal vaccines that provide broad protection and slow viral replication at the entry point of respiratory viruses.
Industries
Nr. of Employees
small (1-50)
ACM Biolabs
Singapore, Central Region, Singapore, Asia
Products
Adjuvanted spike-protein subunit COVID-19 vaccine candidate (Beta variant) — clinical-stage
Protein subunit vaccine candidate formulated with a synthetic immunostimulant and encapsulated in polymeric nanocarriers; evaluated for intramuscular and intranasal administration in early clinical testing.
Thermostable mRNA block-copolymer nanoparticle formulation (preclinical)
Block copolymer-based mRNA nanoparticle formulation intended to improve thermostability and lymphoid targeting; demonstrated immunogenicity and protective efficacy in preclinical animal models.
Adjuvanted spike-protein subunit COVID-19 vaccine candidate (Beta variant) — clinical-stage
Protein subunit vaccine candidate formulated with a synthetic immunostimulant and encapsulated in polymeric nanocarriers; evaluated for intramuscular and intranasal administration in early clinical testing.
Thermostable mRNA block-copolymer nanoparticle formulation (preclinical)
Block copolymer-based mRNA nanoparticle formulation intended to improve thermostability and lymphoid targeting; demonstrated immunogenicity and protective efficacy in preclinical animal models.
Services
Preclinical vaccine formulation and immunogenicity testing
Development of polymer-based vaccine formulations, co-formulation of antigen and adjuvant in nanocarriers, and execution of preclinical immunogenicity and challenge studies to evaluate mucosal and systemic protection.
Formulation and materials development for block copolymers and hybrid nanocarriers
Synthesis, scale-up process development and analytical characterization of amphiphilic block copolymers, lipids and polymer/lipid hybrid nanoparticles for downstream formulation and transfer to manufacturing.
Analytical characterization and GLP safety testing coordination
Material and formulation analytical assays and coordination of GLP toxicology studies to generate data packages for regulatory submissions.
Public–private collaborative program and grant management
Management of collaborative R&D programs and grant-funded partnerships with academic and public-sector groups to advance platform validation and translational studies.
Preclinical vaccine formulation and immunogenicity testing
Development of polymer-based vaccine formulations, co-formulation of antigen and adjuvant in nanocarriers, and execution of preclinical immunogenicity and challenge studies to evaluate mucosal and systemic protection.
Formulation and materials development for block copolymers and hybrid nanocarriers
Synthesis, scale-up process development and analytical characterization of amphiphilic block copolymers, lipids and polymer/lipid hybrid nanoparticles for downstream formulation and transfer to manufacturing.
Analytical characterization and GLP safety testing coordination
Material and formulation analytical assays and coordination of GLP toxicology studies to generate data packages for regulatory submissions.
Public–private collaborative program and grant management
Management of collaborative R&D programs and grant-funded partnerships with academic and public-sector groups to advance platform validation and translational studies.
Expertise Areas
- Block copolymer and polymer/lipid nanoparticle drug delivery
- Thermostable mRNA vaccine delivery and formulation
- Polymersome-based vaccine design
- Mucosal and intranasal vaccine delivery
Key Technologies
- Polymersomes (block copolymer vesicles)
- Polymer–lipid hybrid nanoparticles
- Thermostable mRNA nanoparticle formulations
- Baculovirus–insect cell expression system